Hypha Discovery is a microbial technology company helping partners in pharmaceutical and agrochemical R&D succeed through the discovery and production of microbial and mammalian metabolites. We are experts in the scalable production of DMPK metabolites and generation of polar analogues, and are also a leading provider of unique natural product screening libraries and associated services.
NEWS & EVENTS
27th – 28th October, Sheraton Boston Hotel, Boston, MA
Hypha will present a poster titled: Scaled-up production of human glucuronidated, oxidative and gut metabolites of Epacadostat, an investigational new drug targeting the enzyme Indoleamine 2,3-Dioxygenase 1.
We look forward to seeing you in Boston.
5th December, Oxford University, UK
Meet us at our exhibit in Oxford to learn how Hypha’s biocatalysis system can be applied for late stage functionalization. Our platform allows production and scale up of compound derivatives for SAR studies, improved solubility and bioavailability, and also creates handles for further derivatization at aliphatic and aromatic positions.
Hypha presented a joint poster with Incyte at the 2016 Drug Discovery Chemistry conference in San Diego. The poster titled “Biocatalytic C-H Activation of the JAK Inhibitor Ruxolitinib” describes how Hypha’s microbial-based biocatalytic technology was applied to produce an array of hydroxylated and further oxidised keto metabolites of first-in-class JAK inhibitor ruxolitinib. Download a copy here